Alnylam Pharmaceuticals (ALNY) EBIT (2016 - 2025)
Historic EBIT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $368.0 million.
- Alnylam Pharmaceuticals' EBIT rose 57848.9% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.7 million, marking a year-over-year increase of 24070.11%. This contributed to the annual value of -$176.9 million for FY2024, which is 3731.37% up from last year.
- Alnylam Pharmaceuticals' EBIT amounted to $368.0 million in Q3 2025, which was up 57848.9% from -$16.2 million recorded in Q2 2025.
- In the past 5 years, Alnylam Pharmaceuticals' EBIT ranged from a high of $368.0 million in Q3 2025 and a low of -$258.0 million during Q3 2022
- Moreover, its 5-year median value for EBIT was -$146.2 million (2021), whereas its average is -$83.3 million.
- In the last 5 years, Alnylam Pharmaceuticals' EBIT plummeted by 13595.93% in 2024 and then skyrocketed by 57848.9% in 2025.
- Over the past 5 years, Alnylam Pharmaceuticals' EBIT (Quarter) stood at -$194.6 million in 2021, then rose by 3.06% to -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then rose by 9.66% to -$105.2 million in 2024, then surged by 449.93% to $368.0 million in 2025.
- Its EBIT stands at $368.0 million for Q3 2025, versus -$16.2 million for Q2 2025 and $18.1 million for Q1 2025.